Indonesia's state-owned pharma company strikes deal to manufacture Merck's HPV vaccine - Endpoints News

Cer­vi­cal can­cer is the sec­ond most fre­quent form of can­cer among women in In­done­sia. In ad­di­tion to rais­ing aware­ness and en­cour­ag­ing women to get the HPV shot, the coun­try is now look­ing to man­u­fac­ture Mer­ck’s vac­cine.

The In­done­sian state-owned phar­ma­ceu­ti­cal com­pa­ny Bio Far­ma an­nounced on Tues­day it has signed a con­tract with Mer­ck to lo­cal­ly pro­duce the MSD 4-va­lent HPV vac­cine.

Ac­cord­ing to a trans­lat­ed news re­lease, Mer­ck and Bio Far­ma have had a re­la­tion­ship since 2016. While the HPV vac­cine is cur­rent­ly in use through­out the coun­try, the gov­ern­ment plans to scale up im­mu­niza­tions in 2023.

Mer­ck did not have any fur­ther in­for­ma­tion to share with End­points News on the deal, in­clud­ing on the scale of pro­duc­tion or a time­line for man­u­fac­tur­ing.

Ac­cord­ing to the lat­est num­bers from the HPV In­for­ma­tion Cen­tre, In­done­sia has a pop­u­la­tion of around 99.8 mil­lion women aged 15 and old­er who are at risk of de­vel­op­ing cer­vi­cal can­cer. Around 36,000 women are di­ag­nosed with cer­vi­cal can­cer and around 21,000 women die from the dis­ease in the coun­try each year, ac­cord­ing to the cen­ter’s es­ti­mates.

Adblock test (Why?)

Read Again https://news.google.com/__i/rss/rd/articles/CBMiaGh0dHBzOi8vZW5kcHRzLmNvbS9pbmRvbmVzaWFzLXN0YXRlLW93bmVkLXBoYXJtYS1jb21wYW55LXN0cmlrZXMtZGVhbC10by1tYW51ZmFjdHVyZS1tZXJja3MtaHB2LXZhY2NpbmUv0gEA?oc=5

Bagikan Berita Ini